IDEXX Laboratories, Inc.

Equities

IDXX

US45168D1046

Medical Equipment, Supplies & Distribution

Market Closed - Nasdaq 04:00:00 2024-03-27 pm EDT 5-day change 1st Jan Change
539.6 USD +1.69% Intraday chart for IDEXX Laboratories, Inc. +1.90% -2.79%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Idexx Laboratories: Superior growth prospects Our Logo
Idexx Laboratories Insider Sold Shares Worth $790,427, According to a Recent SEC Filing MT
Idexx Laboratories Insider Sold Shares Worth $4,525,596, According to a Recent SEC Filing MT
Transcript : IDEXX Laboratories, Inc. Presents at 45th Annual Raymond James Institutional Investors Conference 2024, Mar-04-2024 11:00 AM
Ancora seeks four board seats at Elanco amid push for changes RE
Transcript : IDEXX Laboratories, Inc. Presents at Bank of America 2024 Animal Health Virtual Summit, Feb-29-2024 10:50 AM
Ancora seeks four board seats at Elanco amid push for changes, sources say RE
ANALYST RECOMMENDATIONS : Coinbase, Fortinet, Nike, Chipotle, Nvidia... Our Logo
Idexx Launches Vellotm, an Innovative Pet Owner Engagement Software Solution, Streamlining How Practices and Clients Connect CI
Pet products maker Zoetis sees annual profit below estimates on weak demand RE
Idexx Laboratories Insider Sold Shares Worth $6,871,319, According to a Recent SEC Filing MT
Idexx Laboratories Insider Sold Shares Worth $13,295,975, According to a Recent SEC Filing MT
Idexx Laboratories Insider Sold Shares Worth $4,704,559, According to a Recent SEC Filing MT
JPMorgan Adjusts Price Target on IDEXX Laboratories to $630 From $600, Maintains Overweight Rating MT
Morgan Stanley Lifts PT on IDEXX Laboratories to $620 From $600 After 'Impressive' Q4 2023 Upside, 'Solid' 2024 Guide; Overweight Kept MT
Barclays Adjusts Price Target on IDEXX Laboratories to $655 From $605, Keeps Overweight Rating MT
Stifel Adjusts Price Target on IDEXX Laboratories to $570 From $525, Keeps Hold Rating MT
IDEXX Laboratories Shares Rise After Q4 Beat MT
IDEXX Laboratories Seeks Acquisitions CI
Transcript : IDEXX Laboratories, Inc., Q4 2023 Earnings Call, Feb 05, 2024
IDEXX Laboratories sees 2024 revenue above estimates RE
IDEXX Laboratories' Q4 Earnings, Revenue Increase MT
Earnings Flash (IDXX) IDEXX LABORATORIES Posts Q4 Revenue $901.6M, vs. Street Est of $890.6M MT
Tranche Update on IDEXX Laboratories, Inc.'s Equity Buyback Plan announced on August 13, 1999. CI
IDEXX Laboratories, Inc. Provides Financial Guidance for 2024 CI
Chart IDEXX Laboratories, Inc.
More charts
IDEXX Laboratories, Inc. is a world leader in the design, development and marketing of diagnostic test instruments for animal health monitoring and analysis of dairy products and water. Net sales break down by area of application as follows: - veterinary diagnoses for pets (91.6%); - water quality analysis (4.6%); - veterinary diagnoses for livestock and poultry (3.3%): solutions that help detect infectious diseases in ruminants, pigs, poultry and horses. The group also offers test solutions for dairy products; - other (0.5%). Net sales by source of income break down between product sales (57.1%) and services (42.9%). Net sales are distributed geographically as follows: the United States (65.3%), Canada (4.1%), Americas (2.3%), Germany (4.1%), the United Kingdom (3.3%), France (2.7%), Italy (1.5%), Spain (1.4%), Switzerland (0.9%), the Netherlands (0.8%), Europe/Middle East/Africa (4.8%), Australia (2.6%), Japan (2.1%), China (1.2%) and Asia/Pacific (2.9%).
Calendar
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B+
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
14
Last Close Price
539.6 USD
Average target price
585.8 USD
Spread / Average Target
+8.57%
Consensus
  1. Stock
  2. Equities
  3. Stock IDEXX Laboratories, Inc. - Nasdaq
  4. News IDEXX Laboratories, Inc.
  5. Morgan Stanley Adjusts IDEXX Laboratories' Price Target to $603 from $732, Keeps Overweight Rating